A phase II trial of LN 145 for the treatment of cervical cancer
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs LN 145 (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
- 04 Nov 2016 According to a Lion Biotechnologies media release, this trial is expected to begin in 2017.
- 17 May 2016 New trial record